Neurocrine Biosciences stock

NBIX · NASDAQ · USD

Compare Neurocrine Biosciences
$165.92Change from previous close: +0.37%Absolute change: +$0.61

Close · November 17, 2026

Price history

+15.12% over the period

1 year: from $143.56 (November 17, 2025) to $165.27 (November 17, 2026), +15.12%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$165.27
October 30, 2026$146.10
September 30, 2026$141.84
August 31, 2026$154.03
July 31, 2026$166.80
June 30, 2026$168.54
May 29, 2026$158.30
April 30, 2026$131.67
March 31, 2026$131.74
February 27, 2026$132.25
January 30, 2026$136.06
December 31, 2025$141.83
November 28, 2025$152.16
November 17, 2025$143.56

At a glance

  • The company

    Discover and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders

  • Latest results

    Quarter to September 30, 2026 · EPS $3.29 (estimate $1.91)

TickerLandia's take on Neurocrine Biosciences

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$122.14
52-wk high$186.12

−10.85% from the 52-week high

Analysts · 28 analysts

Average target$208.54+25.69% vs. price

Buy 24 · Hold 4 · Sell 0 · Strong buy

TickerLandia Fingerprint: Neurocrine Biosciences

Compared with similar companies: high growth, high financial strength, and high profitability.

Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Neurocrine Biosciences is cheaper than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Neurocrine Biosciences's P/E today is 35.4, below the median of its last 7 fiscal years (53.3; between 23.0 and 275.6 from 2019 to 2025). Neurocrine Biosciences's P/E (trailing 12 months): 24.5, in line with the median of a group of 9 similar companies (24.5).

P/E compared with its history

Compared with 9 similar companies

Neurocrine Biosciences's metrics compared with similar companies
MetricNeurocrine BiosciencesPosition in the groupBand
P/E (trailing 12 months)24.5Middle
Forward P/E13.4Low
Operating margin26.6%Middle
ROE20.4%High
Debt/equity0.12Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Neurocrine Biosciences. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.12B

Latest quarter · Q3 2026

Net income

$206.5M

Latest quarter · Q3 2026

Quarterly net margin

18.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$16.73B
P/E
24.5
EPS
$6.74
Volume
1.31M
Daily trading
€209.11M
Dividend yield
0.00%
Last ex-dividend on December 29, 1995

How Neurocrine Biosciences is changing

All results
  • Revenue grew 22.3% a year on average over the last 5 years

  • Operating margin rose from 16.7% to 21.6%

  • Profits turn into cash: free cash flow equal to 156% of net income

Returns

Neurocrine Biosciences returns

$1,000 invested in Neurocrine Biosciences 5 years ago, on November 17, 2021, would be worth $1,845 today: +84.45% in total, +13.03% per year. This is the price return only: dividends are excluded.

PeriodNeurocrine BiosciencesS&P 500$1,000 becomes
1 month+20.65%−3.17%$1,207
6 months+4.73%+0.11%$1,047
Year to date+16.53%+8.34%$1,165
1 year+15.12%+11.15%$1,151
3 years+51.71%+64.30%$1,517
5 years+84.45%+58.18%$1,845
10 years+216.19%+239.10%$3,162

Over the last 6 months it has done better than 31% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Neurocrine Biosciences: technical analysis

Neurocrine Biosciences shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 10.6% below its all-time closing high ($185.50, July 30, 2026).

Trend
No clear trend
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+11.23%

Support and resistance

Price areas where Neurocrine Biosciences has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$169.29+2.03%2 touches, last on July 16, 2026
  2. Last price$165.92
  3. Support$161.00−2.97%3 touches, last on September 2, 2026
  4. Support$153.42−7.54%4 touches, last on August 31, 2026
  5. Support$147.85−10.89%2 touches, last on October 5, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.71
Volatility (60 sessions, annualised)
37.8%
Largest fall in the last year
−27.15%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Neurocrine Biosciences: seasonality

Average monthly price change over 31 years

+6.4%Jan−1.5%Feb−0.9%Mar−1.2%Apr+5.4%May+2.1%Jun−0.2%Jul+1.9%Aug+2.4%Sep+3.0%Oct+3.9%Nov+4.0%Dec

Over the last 31 years, the strongest month for Neurocrine Biosciences has been January: +6.41% on average, positive in 15 years out of 30. The weakest has been February: −1.54% on average, positive in 9 years out of 30. November, the current month, has been positive in 18 years out of 30 (+3.94% on average).

Show chart data
MonthAverageMedianPositive years
January+6.41%+1.01%15 of 30
February−1.54%−2.90%9 of 30
March−0.88%−1.32%12 of 30
April−1.21%−2.73%10 of 30
May+5.40%+7.24%18 of 30
June+2.10%+1.67%17 of 31
July−0.21%−0.93%15 of 31
August+1.95%+1.52%16 of 31
September+2.37%+0.56%17 of 31
October+2.98%+2.61%18 of 31
November+3.94%+4.30%18 of 30
December+4.01%+3.07%19 of 30

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Neurocrine Biosciences and its competitors

Neurocrine Biosciences sells its medicines mainly to patients with neurological and psychiatric disorders, and to patients with endocrine and immunological conditions, in the United States and in other markets outside the country. Its marketed products include INGREZZA, for tardive dyskinesia and chorea linked to Huntington's disease, Orilissa and Oriahnn for gynecological conditions, and CRENESSITY for congenital adrenal hyperplasia, alongside ALKINDI and Efmody. Its pipeline in clinical development targets movement disorders, major depressive disorder, schizophrenia, Alzheimer's disease, epilepsy and obesity.

Headquarters
San Diego, United States
Employees
2,500
Founded
1992
Chief executive
Kyle Gano
Neurocrine Biosciences and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Neurocrine BiosciencesNBIX$16.73B26.6%24.5+4.73%
ViatrisVTRS$23.58B——+24.09%
United TherapeuticsUTHR$25.04B39.4%22.2+2.73%
ZoetisZTS$33.92B37.9%14.1+12.48%
Teva Pharmaceutical IndustriesTEVA$49.67B19.8%99.0+24.29%
Hims & Hers HealthHIMS$4.13B-6.4%—−29.94%

Same industry or related industries, similar size. Compare Neurocrine Biosciences with its competitors · Full profile